Patents Assigned to Smivet B.V.
  • Tetanus prophylaxis
    Publication number: 20240376185
    Abstract: The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus.
    Type: Application
    Filed: April 30, 2024
    Publication date: November 14, 2024
    Applicant: Smivet B.V.
    Inventors: Abraham Johannes de Smit, Michaël Marie Harmsen
  • Single domain antibodies binding to tetanus neurotoxin
    Patent number: 12054540
    Abstract: The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 6, 2024
    Assignee: Smivet B.V.
    Inventors: Abraham Johannes de Smit, Michaël Marie Harmsen
  • SINGLE DOMAIN ANTIBODIES BINDING TO TETANUS NEUROTOXIN
    Publication number: 20220275066
    Abstract: The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 1, 2022
    Applicant: Smivet B.V.
    Inventors: Abraham Johannes de Smit, Michaël Marie Harmsen